The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery.
As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.
Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.
Friedreich’s ataxia (FRDA) is an autosomal recessive disease characterized by loss of coordination and cardiomyopathy. It is the most common form of inherited ataxia with an incidence in 1/50,000 in the Caucasian population.
In this protocol, we plan to prospectively recruit subjects with chronic kidney disease or end stage kidney disease on dialysis.
Either male or female, ages 18 to 95, chronic kidney disease (with estimated GFR; 60 ml/min/1.73 m2).
The objectives of our study are: (1) to use our validated urinary cell 3-gene signature to prevent the development of clinical rejection; and (2) to use our validated urinary biomarkers that noninvasively diagnose clinical rejection and avoid performing a diagnostic kidney transplant biopsy.
The purpose of this study is to prospectively evaluate the incidence of blood-flow compromise and to obtain long-term survival data on patients implanted with the Amplatzer Septal Occluder.
This study is for patients who have breast cancer that has spread to the lymph nodes under the arm (in the arm pit) and have been treated with chemotherapy.
- Age 18 years or older
- Breast cancer that has spread to the lymph nodes under the arm (in the arm pit) and treated with chemotherapy
- Detailed eligibility reviewed when you contact the study team
This is a clinical trial for women with newly diagnosed ductal carcinoma in situ (DCIS).
- Open to women age 40 and older
- Newly diagnosed with ductal carcinoma in situ (DCIS)
- Detailed eligibility will be reviewed when you contact the study team
This research study is for men and women who are diagnosed with ventricular tachycardia suitable for ablation. The purpose of the study is to assess the utility of an imaging procedure known as contrast-enhanced intracardiac echocardiography (ICE) in this procedure.
This research study is for men and women who are diagnosed with heart failure with normal ejection fraction (HFNEF). The purpose of the study is to assess the role of coronary artery disease (CAD) in persons with HFNEF. This study does not involve any investigative medical intervention.
This two-part, part 1: open-label extension (OLE) and part 2: safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate to severe ulcerative colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies.
Part 1 (Open-label Extension)
- Participants previously enrolled in the Phase II OLE study or Phase III controlled studies who meet the eligibility criteria for open-label etrolizumab for those studies as described in the protocol
Part 2 (Safety Monitoring)
- Participants whose safety follow-up or PML follow-up is not completed within Study GA27927 and participants who had their last dose of etrolizumab in July 2016 in Study GA27927 and are not eligible or willing to enroll in Part 1 (OLE)
- Participants who participated in one of the etrolizumab Phase III studies and are not eligible or willing to enter Part 1 (OLE)
- Participants who transfer from Part 1 (OLE)
- Completion of the 12-week safety follow-up prior to entering.
Part 1 (Open-label Extension)
- Withdrawal of consent from and participant not compliant in the Phase II OLE study or any of the Phase III studies
- Participant who discontinued etrolizumab/etrolizumab placebo prior to Week 10 or did not perform the Week 10 visit of the Phase III Studies GA28948, GA28949, GA29102, and GA29103
- Participant who discontinued etrolizumab/etrolizumab placebo prior to Week 14 or did not perform the Week 14 visit of the Phase III Study GA28950
- Any new, significant, uncontrolled condition